Hepatic Encephalopathy Market expected to rise | Companies – Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix

Hepatic Encephalopathy Market expected to rise | Companies - Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix
Hepatic Encephalopathy Market
DelveInsight’s ‘Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The Hepatic Encephalopathy market growth is driven by factors like increase in the prevalence of Hepatic Encephalopathy, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Hepatic Encephalopathy market report also offers comprehensive insights into the Hepatic Encephalopathy market size, share, Hepatic Encephalopathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hepatic Encephalopathy market size growth forward. 

Some of the key highlights from the Hepatic Encephalopathy Market Insights Report:

  • Several key pharmaceutical companies, including Salix Pharmaceuticals, Bausch Health, Axcella Health, Umecrine Cognition, Vedanta Biosciences, Patricia Bloom, Rebiotix, and others, are developing novel products to improve the Hepatic Encephalopathy treatment outlook. 
  • The total Hepatic Encephalopathy market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Hepatic Encephalopathy market is anticipated to witness growth at a considerable CAGR
  • The Hepatic Encephalopathy market size in seven major markets was USD 1,563 million in 2021, which is further expected to increase by 2032.
  • Total diagnosed prevalent cases of Cirrhosis (hospitalized) in the 7MM was found to be 862,508 cases in 2021. These cases are expected to increase by 2032 at a CAGR of 0.63% during the study period (2019–2032).

Strategise your business goals by understanding market dynamics @ Hepatic Encephalopathy Market Landscape

Hepatic Encephalopathy Overview 

Hepatic encephalopathy (HE) is a brain disorder that develops in some individuals with liver disease. HE presents as a spectrum of neuropsychiatric symptoms ranging from subtle fluctuating cognitive impairment to coma and is a significant contributor to morbidity in patients with liver disease. It is observed in acute liver failure, liver bypass procedures – for example, shunt surgery and trans-jugular intrahepatic portosystemic shunt – and cirrhosis, classified as Type A, B, and C HE, respectively.

Moreover, Hepatic Encephalopathy can be associated with more severe symptoms, including reduced alertness, shortened attention span, disruptions in sleep patterns, mild confusion, slowing ability to perform mental tasks, and mood or personality changes. More noticeable changes in memory, concentration, or intellectual function than in minimal hepatic encephalopathy (MHE) may also be observed.

The pathophysiology of Hepatic Encephalopathy is multifactorial and involves agents such as ammonia (NH3), inflammatory cytokines, manganese deposition in the basal ganglia, and benzodiazepine-like compounds (i.e., gamma-aminobutyric acid [GABA]); recent studies have also recognized roles of microbiota and aromatic amino acids. Although HE pathogenesis is a complex entity with multiple components resulting in functional impairment of neuronal cells—none of which are well understood—NH3 has been considered the primary pathophysiologic mechanism of HE.

Hepatic Encephalopathy is classified into two broad categories based on severity, covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE). When affected individuals have obvious, outward signs and symptoms, the disorder may be referred to as OHE.

Hepatic Encephalopathy (HE) Diagnosis

Defining and diagnosing Hepatic Encephalopathy, particularly CHE, remains challenging. In CHE, there are no clinical signs or symptoms; however, patients have neuropsychological deficiencies that can be detected with psychometric or neuropsychological testing.

The Hepatic Encephalopathy diagnosis is based on the presence of a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction after excluding unrelated neurologic and/or metabolic causes of encephalopathy.

Hepatic Encephalopathy (HE) Treatment

The treatment of acute or persistent HE has changed very little during the past 40 years. However, with newer agents under investigation, the available treatment options will increase over 5 years. Until then, treatment options are limited to correcting or removing precipitating causes, dietary changes, and pharmacologic approaches that are focused on the use of non-absorbable disaccharides. Additional pharmacological agents available include certain antibiotics, drugs to eliminate ammonia from the plasma, and a few other drugs with special indications.

Management of OHE includes treating patients with acute Hepatic Encephalopathy episodes, preventing Hepatic Encephalopathy recurrence, and identifying and managing precipitating factors associated with HE development. The two primary forms of medical therapy for HE are non-absorbable disaccharides (i.e., lactitol and lactulose) and non-absorbable antibiotics (i.e., Rifaximin).

The hyperammonemia and inflammation that occurs due to urea breakdown in cirrhosis have led to the development of HE treatments that target gut bacteria. Treatments for OHE are approved by the US FDA while some unapproved therapies are also available for use. It is important to remember that in patients with cirrhosis and portosystemic shunting, skeletal muscle mass and renal clearance are vital to neurotoxin clearance.

Do you know the treatment paradigms for different countries? Download our Hepatic Encephalopathy Market Sample Report

Recent Breakthroughs in the Hepatic Encephalopathy Market:

FDA Approves XIFAXAN® 550 Mg Tablets For Reduction In Risk Of Overt Hepatic Encephalopathy (HE) Recurrence: XIFAXAN 550 mg Tablets Offer First Clinical Treatment Option in the United States for Patients with Overt HE in More Than 30 Years

Hepatic Encephalopathy Epidemiology Segmentation 

DelveInsight’s Hepatic Encephalopathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hepatic Encephalopathy historical patient pools and forecasted Hepatic Encephalopathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hepatic Encephalopathy Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Hepatic Encephalopathy Prevalence 
  • Age-Specific Hepatic Encephalopathy Prevalence 
  • Gender-Specific Hepatic Encephalopathy Prevalence 
  • Diagnosed and Treatable Cases of Hepatic Encephalopathy

Visit for more @ Hepatic Encephalopathy Epidemiological Insights

Hepatic Encephalopathy Treatment Market 

The Hepatic Encephalopathy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hepatic Encephalopathy market trends by analyzing the impact of current Hepatic Encephalopathy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Hepatic Encephalopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hepatic Encephalopathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hepatic Encephalopathy market in 7MM is expected to witness a major change in the study period 2019-2032.

Hepatic Encephalopathy Key Companies

  • Salix Pharmaceuticals
  • Bausch Health
  • Axcella Health, Inc.
  • Umecrine Cognition
  • Vedanta Biosciences
  • Patricia Bloom
  • Rebiotix

For more information, visit Hepatic Encephalopathy Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Hepatic Encephalopathy Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Hepatic Encephalopathy, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Hepatic Encephalopathy epidemiology in the 7MM
  • Hepatic Encephalopathy marketed and emerging therapies 
  • Hepatic Encephalopathy companies
  • Hepatic Encephalopathy market drivers and barriers 

Key Questions Answered in the Hepatic Encephalopathy Market Report 2032:

  • What was the Hepatic Encephalopathy market share distribution in 2019, and how would it appear in 2032?
  • What is the total Hepatic Encephalopathy market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Hepatic Encephalopathy market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Hepatic Encephalopathy market projected to expand at 7MM?

Table of Contents:

1 Hepatic Encephalopathy Market Key Comprehensive Insights 

2 Hepatic Encephalopathy Market Report Introduction

3 Competitive Intelligence Analysis for Hepatic Encephalopathy

4 Hepatic Encephalopathy Market Analysis Overview at a Glance

5 Executive Summary of Hepatic Encephalopathy

6 Hepatic Encephalopathy Epidemiology and Market Methodology

7 Hepatic Encephalopathy Epidemiology and Patient Population

8 Hepatic Encephalopathy Patient Journey

9 Hepatic Encephalopathy Treatment Algorithm, Hepatic Encephalopathy Current Treatment, and Medical Practices

10 Key Endpoints in Hepatic Encephalopathy Clinical Trials

11 Hepatic Encephalopathy Marketed Therapies 

12 Hepatic Encephalopathy Emerging Therapies

13 Hepatic Encephalopathy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Hepatic Encephalopathy

16 Hepatic Encephalopathy Market Key Opinion Leaders Reviews

18 Hepatic Encephalopathy Market Drivers

19 Hepatic Encephalopathy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Hepatic Encephalopathy Epidemiology 2032

DelveInsight’s “Hepatic Encephalopathy – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Hepatic Encephalopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Hepatic Encephalopathy Pipeline 2023

“Hepatic Encephalopathy Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hepatic Encephalopathy market. A detailed picture of the Hepatic Encephalopathy pipeline landscape is provided, which includes the disease overview and Hepatic Encephalopathy treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/